Moyang Biotechnology
Chinese high-tech enterprise, has researched and developed their own patent products for aesthetics, skin-collapse treatments and other medical fields.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
* | CNY200m | Late VC | |
| Total Funding | 000k | ||
Related Content
Shanghai Moyang Biotechnology Co., Ltd. operates as a research and development-driven enterprise within China's medical aesthetics sector. The firm concentrates on the development, production, sales, and provision of consulting services for its specialized products.
The company's strategic focus is on creating a material platform centered on calcium microspheres and carboxymethylcellulose (CMC) gels. This positions Moyang Biotechnology in the market for anti-aging skin treatments. The business operates on a B2B model, manufacturing and supplying its products to the medical aesthetics industry. Its core business involves the entire lifecycle of its products, from initial research and innovation to manufacturing and sales.
Moyang's product pipeline includes superficial anti-aging skin products currently being marketed. The company's core offering, a product named "Moyan Microcrystalline," has advanced to the registration and evaluation stage as a national Class III medical device in China, indicating a significant step towards commercialization. The company has received investment from firms including BlueRun Ventures and HUAGAI Capital.
Keywords: medical aesthetics, calcium microspheres, CMC gels, anti-aging, dermatology, cosmetic fillers, regenerative medicine, Chinese biotechnology, aesthetic medicine, skincare, Moyan Microcrystalline, Class III medical device, injectable fillers, collagen stimulators, cosmetic biotechnology, non-surgical aesthetics, facial rejuvenation, dermal fillers, biopharmaceutical, healthtech